Sept. 6, 2013
/PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the appointment of
Ted W. Love
, M.D., to its board of directors.
"We are pleased to welcome Dr. Love, with his extensive experience in drug development, operations and corporate governance, to our board of directors," said
Robert L. Kirkman
, M.D., President and Chief Executive Officer of Oncothyreon.
Dr. Love served as Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc., from
. From 2001 to
, Dr. Love served as Chairman and Chief Executive Officer of Nuvelo, Inc. Dr. Love joined Nuvelo from Theravance, Inc., where he served as Senior Vice President of Development from 1998 to 2001. Previously, he spent six years at Genentech, Inc., where he held a number of senior management positions in medical affairs and product development and served as chairman of Genentech's Product Development Committee. Dr. Love also serves as a member of the boards of directors of biopharmaceutical companies Santarus, Inc., Amicus, Inc., and Kalobios, Inc. Until
, he served on the California Independent Citizens' Oversight Committee. Dr. Love earned his Bachelor of Science in molecular biology from
and his M.D. from
Yale Medical School
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit
Additional information relating to Oncothyreon can be found on EDGAR at
and on SEDAR at
SOURCE Oncothyreon Inc.